|
 The drug, used to treat adults with acromegaly for whom surgery is
not an option, was approved after two late-stage studies showed the
drug allowed for greater disease control than existing therapies,
Novartis said.
Acromegaly is caused by a benign tumor in the pituitary gland that
secretes excess growth hormone, and can lead to the enlargement of
body parts, including the hands, feet and facial features.
An estimated one to two people per 10,000 are affected with the
disease in the European Union, according to Novartis.
(Reporting by Caroline Copley; Editing by Prateek Chatterjee)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
|
